Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Finger-Prick test replace blood draws for kidney patients?

NCT ID NCT07777523

Diagnosis Sponsor: Gisens Biotech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study evaluates a portable digital test called KF4+ that measures urea and potassium from a tiny drop of capillary blood, like a finger prick. The trial involves 55 adults with end-stage kidney disease who are on dialysis. The goal is to see if the KF4+ results match standard hospital lab tests done on venous blood, and whether it can also help assess dialysis efficiency. If it works, this could make routine monitoring easier and less invasive for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KF4+ noninvasive digital test for measuring urea and potassium in capillary blood
What this could lead to
If successful, this could enable simpler, more convenient monitoring of kidney dialysis patients, potentially reducing the need for frequent venous blood draws.
What could go wrong
This is a small observational study, and the test's accuracy compared to standard lab methods is not yet proven. It may not be reliable enough for routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

Oct 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

End-Stage Chronic Kidney Disease Patients under Chronic Dialysis from Hospital Interzonal General de Agudos General San Martín La Plata, Argentina

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years) * Diagnosis of end-stage renal disease * Receiving chronic dialysis treatment * Receiving chronic hemodialysis treatment * Able and willing to provide written informed consent Exclusion Criteria: * Inability to provide informed consent * Any condition that, in the opinion of the investigator, would interfere with participation or data interpretation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dialysis patients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure uremia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dialysis patients Noninvasive Potassium measurement Renal disease, chronic Renal disease, end-stage Urea in blood; high

Contacts and locations

Locations

  • Hospital Interzonal General de Agudos General San Martín La Plata, Argentina

    La Plata, Buenos Aires, 1900, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.